ISPO

Published in Cancer Detection and Prevention 1999; 23(2):129-136.

Analysis of SAS gene, CDK4 and MDM2 Proteins in Low-Grade Osteosarcoma

P. Ragazzini, M.S.,1 G. Gamberi, M.S.,1 M. S. Benassi, M.S.,1 C. Orlando, M.D.,2 R. Sestini, M.S.,2 C. Ferrari, M.S.,1 L. Molendini, M.S.,1 M. R. Sollazzo, M.S.,1 M. Merli, M.S.,1 G. Magagnoli, M.S.,1 F. Bertoni, M.D.,1 T. Bohling, M.D.,3 M. Pazzagli, M.D.,2 P. Picci, M.D.1

1Laboratory of Oncologic Research, Rizzoli Orthopedic Institute, Bologna, Italy; 2Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Italy; 3Department of Pathology, Haartman Institute, University of Helsinki, Finland

Address all correspondence and reprint requests to: Maria Serena Benassi, Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy Tel: 051/6366767 Fax: 051/6366761 E-mail: Benassi@pt.tizeta.it

ABSTRACT: The region q13-15 of chromosome 12 contains SAS, CDK4, MDM2 genes that are rearranged or amplified in a variety of human sarcomas. This study evaluated SAS gene amplification, and MDM2 and CDK4 protein expression in 20 tumor samples of central low-grade osteosarcoma (16 primary, 3 recurrences, 1 lung metastasis). SAS amplification was analyzed by quantitative PCR, while from the same paraffin-embedded samples, MDM2 and CDK4 protein expression was evaluated by immunohistochemistry MDM2 and CDK4 proteins were found strongly expressed respectively in 35% and 65% of the samples. SAS was found amplified in 15% of the samples. These findings indicate that these genes may be involved in tumorigenesis and progression of low-grade osteosarcoma.

For more information, contact gabriella.gamberi@ior.it

http://www.cancerprev.org/Journal/Issues/23/2/316